• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    2/1/24 4:01:33 PM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email
    false 0001786511 00-0000000 0001786511 2024-01-31 2024-01-31 0001786511 FRES:AmericanDepositarySharesEachRepresenting20ClassOrdinarySharesParValueUs0.01PerShareMember 2024-01-31 2024-01-31 0001786511 FRES:ClassOrdinaryShareParValueUs0.01PerShareMember 2024-01-31 2024-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 31, 2024

     

    Fresh2 Group Limited
    (Exact name of registrant as specified in its charter)

     

    British Virgin Islands   001-39137   Not Applicable
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    650 5TH AVE STE 2416

    NEW YORK,

    United States

      NY 10019-6108
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 917-397-6890

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    American depositary shares (each representing 20 Class A ordinary shares, par value US$0.01 per share)   FRES   Nasdaq Capital Market
    Class A ordinary share, par value US$0.01 per share        

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 8.01. Other Events.

     

    On January 31, 2024, Fresh2 Group Limited (the “Company”) issued a press release announcing the receipt of a deficiency notice (the “Notice”) from The Nasdaq Stock Market informing the Company that it failed to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

     

    The foregoing description of the Notice does not purport to be complete and is qualified in its entirety by reference to the Notice, the form of which is filed as Exhibit 4.1 hereto and is incorporated herein by reference.

     

    Item 9.01. Financial Statement and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No   Document
    99.1   Press Release dated January 31, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: February 1, 2024 Fresh2 Group Limited
       
      By: /s/ Haohan Xu
      Name:  Haohan Xu
      Title: Chief Executive Officer

     

     

    2

     

    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    SEC Filings

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care